Publications by authors named "T M Dolores"
Eastern Spanish experience with nivolumab in metastatic renal cell carcinoma.
Clin Transl Oncol
September 2020
Article Synopsis
- Nivolumab is being evaluated for its effectiveness and safety as a second-line treatment for advanced metastatic renal cell carcinoma (mRCC) in Eastern Spanish patients who have experienced progression after TKI therapy.
- A study analyzed data from 98 mRCC patients, mainly male, with most receiving prior treatment (like sunitinib or pazopanib) and having a median treatment duration of 3.6 months.
- Results indicated a 25% confirmed response rate, with median progression-free survival at 7.8 months and overall survival at 16.3 months, while mostly mild side effects were reported, such as hypothyroidism and liver toxicity.